Theravance Biopharma, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rick E. Winningham
- Full Time Employees
- 97
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Ugland House George Town United States of America KY1-1104
- IPO Date
- May 16, 2014
- CIK
- 0001583107
- Website
- theravance.com
- Similar Companies
- Business
- Theravance Biopharma, Inc. (TBPH) is a biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines for specialty respiratory and neurologic diseases. The company offers YUPELRI (revefenacin) inhalation solution, a once-daily nebulized long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in collaboration with Viatris Inc.; receives royalties from GlaxoSmithKline plc (GSK) on sales of TRELEGY Ellipta (fluticasone furoate/umeclidinium/vilanterol), a triple combination LABA/LAMA/ICS therapy for COPD and asthma; and advances ampreloxetine, a late-stage investigational once-daily norepinephrine reuptake inhibitor (NRI) for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Founded in 2014 and headquartered in South San Francisco, California, with additional operations in Dublin, Ireland, Theravance Biopharma targets patients in the United States and select international markets through strategic partnerships. Recent developments include the June 2025 sale of its remaining royalty interest in TRELEGY to GSK for $225 million to maximize shareholder value; Viatris' receipt of China National Medical Products Administration (NMPA) approval for YUPELRI in June 2025, triggering a $7.5 million milestone payment and potential sales-related milestones plus royalties; completion of enrollment in the pivotal Phase 3 CYPRESS study of ampreloxetine in MSA patients in August 2025, with topline data expected in Q1 2026 and plans for a new drug application submission; and strong YUPELRI demand growth of 6% year-over-year in Q3 2025 alongside Viatris collaboration revenue up 19%.
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
Theravance Stock Declines Around 17% in Three Months: Here's Why
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
Theravance's Q4 Earnings and Revenues Miss Estimates